Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 2/20 | 0.36 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.36 |
| ▸ | S1PR5 | Q9H228 | 2/20 | 0.36 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.33 |
| ▸ | GNAO1 | P09471 | 2/20 | 0.30 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.30 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.30 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18524944 | 0.83 | S1PR1 (0.33) | S1PR1S1PR3S1PR5 | |
| SCHEMBL20901286 | 0.82 | LTA4H (0.38) | GNAO1GNAI3GNAI1 | |
| SCHEMBL14098302 | 0.80 | LTA4H (0.35) | GNAO1GNAI3GNAI1SIGMAR1 | |
| SCHEMBL24335467 | 0.79 | GNAO1 (0.40) | S1PR1S1PR3S1PR5GNAO1GNAI3 | |
| SCHEMBL26941906 | 0.79 | GNAO1 (0.43) | GNAO1GNAI3GNAI1SIGMAR1 | |
| SCHEMBL22430288 | 0.79 | GNAO1 (0.43) | GNAO1GNAI3GNAI1SIGMAR1 | |
| SCHEMBL26014660 | 0.78 | NPC1 (0.35) | GNAO1GNAI3GNAI1 | |
| SCHEMBL20803752 | 0.77 | — | — | |
| SCHEMBL19506630 | 0.77 | CNR1 (0.41) | SIGMAR1 | |
| SCHEMBL19261397 | 0.77 | CNR1 (0.41) | SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170044160-A1 | TETRACYCLINE COMPOUNDS | TETRAPHASE PHARMACEUTICALS, INC. | 2017-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170044160-A1 | TETRACYCLINE COMPOUNDS | TUBB, TUBA1C, TUBA1A | S1PR1 3875/4885S1PR3 4151/4885S1PR5 3710/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.